Adenoviral delivery of the p53 gene is a potential therapeutic approach for the treatment of lung cancer. Furthermore, amifostine is a cytoprotective agent and recent reports have described its potentiation of chemotherapy's antitumor activity in lung cancer. Therefore, we wished to investigate the ability of amifostine both alone and in combination with p53-based therapy to induce apoptosis, and to understand the mechanisms by which this apoptosis occurs. Using p53 null and wild-type p53 human lung cancer cells and normal human bronchial epithelial cells, we evaluated the effects of amifostine on proliferation and apoptosis. We then analyzed Adp53 in combination with amifostine and performed isobologram analysis. Expression of p53, p21 WAF1 , Bax, Bak, bcl-2, as well as total and phosphorylated Cdc2 in the absence and presence of olomoucine, a phosphorylated Cdc2 kinase inhibitor, was then determined. Amifostine-induced apoptosis in human lung cancer cells in a dose-dependent fashion. The combination of amifostine and Adp53 significantly enhanced, with a supra-additive effect, the inhibition of proliferation of lung cancer cells. This enhancement of apoptosis by amifostine was associated with activation of p53 and dephosphorylation of Cdc2 proteins. Notably, olomoucine effectively prevented amifostine and/or Adp53-induced Cdc2 kinase activation and subsequent apoptosis. Our data shows that amifostine alone can induce apoptosis of human lung cancer cells, and that the combination of Adp53 with amifostine resulted in significantly higher levels of apoptosis. In addition, it appears that Cdc2 kinase plays an important role in the induction of apoptosis by amifostine and Adp53.
Introduction
Apoptosis, or programmed cell death, has been implicated in various processes such as embryogenesis, carcinogenesis, and immune-mediated cell killing. Apoptosis is morphologically characterized by condensation and fragmentation of nuclear chromatin and cell shrinkage. 1 The molecular mechanisms involved in apoptosis have been partially elucidated and are mediated intracellularly by multiple genes, including p53, 2 Bcl-2, 3 and Bax. 4 Abnormalities of p53 are some of the most frequent molecular events in carcinogenesis, and represent one of the most studied areas in contemporary tumor biology. The tumor-suppressor p53 is a central effector of the response of cells to genotoxic stress. p53 encourages cells to die or arrest when faced with DNA damage, hypoxia, oxidative stress, or telomeric shortening. 5 It has been demonstrated that following DNA damage, p53 is rapidly activated and binds specifically to DNA, which activates the transcription of target genes involved in negative control of the cell cycle and initiation of apoptosis. 6 Several studies have shown that transfection with wild-type p53 can directly drive cells into apoptosis and/ or growth arrest when p53 is overexpressed. 7, 8 Currently, adenoviral delivery of p53 is being explored by multiple investigators across tumor types as a potential therapy for cancer. [9] [10] [11] Amifostine (WR-2721), an amithiol compound, is a cytoprotective agent. In clinical trials in non-small-cell lung cancer, amifostine has been found to significantly reduce the hematologic and nonhematologic toxicity of DNA-damaging agents such as alkylators, platinum compounds, and mitomycin C. Amifostine is currently approved by the Food and Drug Administration for prevention of cumulative renal toxicity associated with repeated infusions of cisplatin in patients with advanced non-small-cell lung cancer. Interestingly, two small trials have indicated that amifostine may also potentiate the antitumor activity of high-dose chemotherapy. A pilot clinical trial in 25 patients with metastatic non-small-cell lung cancer examined the utility of amifostine given before cisplatin on day 1 followed by weekly vinblastine and documented a higher than expected partial response rate of 64% and a 1-year survival rate of 64%. 12 Another small trial, in metastatic melanoma, showed that treatment with amifostine in combination with cisplatin every 3-4 weeks produced response rates of 50%, well above the response rates of less than 20% typically seen with cisplatin alone. 13 The above reports document that amifostine is a cytoprotectant and may also possess antitumor activity. Thus, we were interested in further exploring amifostine's role as an antitumor agent alone and in combination with adenoviral delivery of wild-type p53. We investigated the combined effects of amifostine and an adenoviral vector containing the wild-type p53 gene under control of the cytomegalovirus promoter (Adp53) in human lung cancer cells. We found that amifostine alone induced apoptosis in human lung cancer cells in a dose-dependent fashion. Amifostine in combination with Adp53 significantly enhanced inhibition of cell proliferation in human lung cancer cells compared to either amifostine alone or Adp53 alone.
Materials and methods
Cell culture, reagents, and antibodies The normal human bronchial epithelial (NHBE) cells were obtained from Clonetics (San Diego, CA) and maintained in Bronchial Epithelial Cell Basal medium from Cambrex (East Rutherford, NJ). The human lung cancer cell lines H1299 (p53 null) and A549 (wild-type p53) were obtained from the American Type Culture Collection (Rockville, MD). H1299 and A549 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 mM glutamine, 100 Units/ml penicillin, and 100 mg/ml streptomycin from Life Technologies, Inc. (Grand Island, NY) in a 5% CO 2 atmosphere at 371C. Amifostine was obtained from Alza Corporation (Palo Alto, CA). Monoclonal antibodies to p53, p21, total Cdc2, and Bcl-2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The polyclonal antibody to Tyr-15-phosphorylated Cdc2 was purchased from New England BioLabs (Beverly, MA). The polyclonal antibodies to Bak, Bax, and b-actin were obtained from Santa Cruz Biotechnology.
Adenovirus production
The construction and properties of the Adp53 and Adbgal virus have been reported elsewhere. 14 
Cytotoxicity assay
To evaluate the number of live and dead cells, the cells were stained with 0.2% Trypan blue and counted on a hemocytometer. Cells that demonstrated Trypan blue uptake were interpreted as nonviable.
Flow cytometry analysis
Apoptotic cells were examined by propidium iodide staining and flow cytometry analysis as previously described. 15 Cells were harvested, pelleted by centrifugation and resuspended in phosphate-buffered saline containing 50 mg/ml propidium iodide, 0.1% Triton X-100, and 0.1% sodium citrate. Samples were stored at 41C for 16 h and vortexed before FACS analysis (BectonDickenson FACScan, Mountain View, CA; FL-3 channel).
Western blot analysis
Total cell lysates were prepared by lysing cell monolayers in plates with sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer after rinsing the cells with phosphate-buffered saline. Each lane was loaded with 50 mg of cell lysate protein as determined by BCA protein assay (Pierce, Rockford, IL). After electrophoresis at 20 mA for 2 h, the proteins in the gels were transferred to Hybond-ECL membranes (Amersham Corp., Arlington Heights, IL). The membranes were then blocked with 1% dry milk and 0.1% Tween 20 (Sigma Chemical Co., St Louis, MO) in phosphate-buffered saline and incubated with primary antibodies, washed with Tween 20 Trisbuffered saline and incubated with secondary antibody conjugated with horseradish peroxidase (Amersham). The membranes were developed according to the Amersham ECL protocol.
Statistical analysis and data analysis
The data reported in the figures represents the mean of three or more independent experiments, and the bars show the standard deviations. Analysis of variance and two-tailed Student' t test were used for statistical analysis of multiple groups and pairwise comparison, respectively, with Po0.05 considered significant. The isobologram method of Steel and Peckham, 16 and a curve-fitting analysis were used to determine whether amifostine and Adp53 were supra-additive at the cellular level.
Results
Effect of amifostine on cell proliferation Treatment of two human lung cancer cell lines and NHBE cells for 24 h with amifostine at doses of 0, 4, 8, 16, 32, and 64 mM inhibited proliferation of the lung cancer cells (H1299, A549) but not the NHBE cells (Table 1) . Cell proliferation was inhibited in a dose-dependent fashion, and the antiproliferative effect on H1299 cells (p53 null) was greater than that on A549 cells (wild-type p53) ( Table 1) . 
Induction of apoptosis by amifostine
To determine whether the growth inhibition seen with amifostine was due to a reduction in cell proliferation or an increase in cell death, we examined human lung cancer cells after treatment with amifostine for evidence of apoptosis. Flow cytometric analysis for terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling (TUNEL)-stained cells, indicative of apoptotic cell death, was performed on the three cell lines 24 h following exposure to amifostine. The number of TUNEL-positive cells and the percentage of apoptotic cells were determined. Amifostine induced apoptosis in both lung cancer cell lines but not in NHBE cells ( Table 1 ). The induction of apoptosis was more pronounced in H1299 cells, which are p53 null. To confirm the induction of apoptosis, H1299 lung cancer cells were stained with Hoechst 33342 assay to evaluate for DNA fragmentation. Amifostinetreated H1299 lung cancer cells displayed many apoptotic bodies ( Figure 1 ).
Combined effects of amifostine and Adp53
We then analyzed the interaction of amifostine and Adp53 by examining the effects of increasing multiplicities of infection of Adp53 combined with exposure to increasing concentrations of amifostine for 24 h in H1299 and A549 cells. Cell proliferation was significantly inhibited for both lung cancer cell lines after transfection with Adp53 and exposure to increasing concentrations of amifostine. Flow cytometric analysis showed that for H1299 and A549 cells, administration of amifostine or Adp53 alone resulted in a relatively low percentage of apoptotic cells. However, treating Adp53-transfected cells with amifostine resulted in a substantial enhancement in the percentage of apoptotic cells (Figure 2 ). Of note, H1299 cells (p53 null) treated with Adp53 (multiplicity of infection (MOI) of 1) followed by amifostine (16 mM) had higher rates of apoptosis than H1299 cells treated with Adp53 alone (MOI of 1) ( Figure 2 ). As described above, the inhibitory effect of amifostine and Adp53 on cell proliferation was dose dependent in the H1299 and A549 cell lines. Therefore, an isobologram analysis was performed to evaluate the nature of the interactions (additivity or enhancement) of the two treatments. The data points obtained for combination therapy with amifostine and Adp53 fell within the envelope of the supra-additive area for both the H1299 (Figure 3a ) and A549 (Figure 3b ) cell lines. This suggested that in both cell lines, exposure to amifostine after Adp53 transfection can result in synergistic cell killing. The isobologram patterns of the therapeutic combinations with amifostine and Adp53 were reproduced twice from independent experiments in each cell line.
Expression of p53, p21
WAF1 Cdc2, Bax, Bak, and Bcl-2 To gain insight into the molecular effector pathway of amifostine-induced apoptosis, we evaluated p53 and p21 expression after treatment with amifostine. In both of the lung cancer cell lines, amifostine treatment resulted in an increase in the level of p53 (endogenous or expressed using the Adp53 vector) and a dose-dependent accumulation of p53 protein; however, amifostine treatment did not alter the expression of p21. In an effort to explain the amifostine-induced apoptosis in p53-deficient H1299 cells, we evaluated the level of Cdc2 expression in the two lung cancer cell lines. Cdc2 plays a critical role, together with cyclin B1, in the progression of cells through the G 2 /M phase of the cell cycle and induction of apoptosis. 17 The expression of total Cdc2 remained unchanged in amifostine-treated cells. In contrast, the expression of Tyr-15-phosphorylated Cdc2 protein was decreased significantly A supra-additive effect was seen for the combination of these therapeutic agents (reproduced twice). The envelope of additivity for the two-dimensional isobologram was defined by three isoeffect lines, Mode 1 and two of Mode II (a and b), respectively. When the observed data points for a combination fell mainly within the envelope of additivity, the effect of the combination was considered as having an additive effect. When the observed data points for a combination fell into the area below the envelope of additivity, the combination effect was regarded as supra-additive (synergism). When the observed data points for a combination fell above the envelope but within the square or the cube, the combination's effect was considered as subadditive. When the observed data points for a combination fell outside the square or the cube, the effect of the combination was considered protective. Both subadditive and protective interactions were considered as antagonistic.
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after exposure to amifostine in H1299 cells but not in A549 (wild-type p53) cells. Phosphorylated Cdc2 expression was also decreased after exposure to Adp53 alone in both of the lung cancer cell lines (Figure 4) .
To determine whether dephosphorylation of the Tyr-15-phosphorylated Cdc2 protein was responsible for amifostine-and Adp53-mediated apoptosis in H1299 cells, we treated the cells with olomoucine before treating them with amifostine and/or Adp53. Olomoucine is a specific Tyr-15-phosphorylated Cdc2 kinase inhibitor that has been found to compete with the ATP-binding site of Cdc2. Treatment with 10 mM olomoucine effectively inhibited amifostine-and/or Adp53-induced dephosphorylation of Tyr-15-phosphorylated Cdc2 kinase in H1299 cells (Figure 5a ). Amifostine-and/or Adp53-induced apoptosis was also blocked partially by olomoucine treatment (Figure 5b) . These results confirmed our findings that amifostine plus Adp53 acted in a synergistic fashion to induce apoptosis in H1299 cells through dephosphorylation of Cdc2.
We next used Western blot analysis to determine whether treatment with amifostine altered the expression of the apoptotic mediators Bax, Bak, and Bcl-2. Lysates were prepared from cells following 24 h of exposure to different concentrations of amifostine. The levels of Bax, Bak, and Bcl-2 expression in the H1299 cell line were not significantly affected with the addition of amifostine and Adp53 ( Figure 6 ).
As cyclin B1 plays a pivotal role, together with Cdc2, in the progression of cells through the cell cycle, we examined whether levels of cyclin B1 are altered in lung cancer cells treated with amifostine with or without Adp53 transfection. H1299 lung cancer cells showed a decrease in the level of expression of cyclin B1 with increased concentrations of amifostine, and this decrease appeared to correlate with an increase in apoptosis ( Figure 7 ).
Discussion
Recent studies have added further evidence that amifostine has a role as an antitumor agent. Amifostine has been evaluated as a possible treatment for myelodysplastic syndrome because of its stimulation of bone marrow hematopoiesis. Additional work has shown that amifostine can also exert a direct effect on myelodysplastic syndrome cells through both growth inhibition and apoptosis and that this effect appears to be independent of p53 status. 18 Amifostine has also been noted to decrease angiogenesis and the mRNA levels of vascular endothelial growth factor in chick embryos. 19 In addition, amifostine increased angiostatin and decreased matrix metalloproteinase production in a murine sarcoma model, resulting in a subsequent 20% decrease in pulmonary metastases. 20 The role of p53 in modulating the dual roles that amifostine has as both a cytoprotectant and as an antitumor agent has been explored, with conflicting results. Amifostine was found to activate the tumorsuppressor protein p53 and induce expression of the cyclin-dependent kinase inhibitor p21 WAF1 in the presence of a functional p53 in the breast cancer cell line MCF-7 
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and the mouse fibroblast cell line 3T3, but was unable to induce p21 WAF1 in a p53-disabled breast cancer cell line. 21 Other studies have indicated that the p53 protein allows amifostine to regulate its effects on both apoptosis and cytoprotection. In colon cancer cells amifostine caused p53-proficient cells to arrest in G1 and provided protection against the cytotoxic effects of paclitaxel, but these effects of amifostine were not seen in p53-deficient cells. 22 However, yet another study investigated amifostine's cytoprotection of human glioma cells during radiation therapy and found that it was independent of p53 status. 23 We suggest that amifostine-mediated cell death may result from two different mechanisms. First, in p53-null cells, amifostine-induced apoptosis and G 2 /M arrest appear to be mediated by dephosphorylation of Tyr-15 on Cdc2 proteins. It is known that the Cdc2 kinase is inactivated when Thr-14 and Tyr-15 of Cdc2 are phosphorylated. 24 The phosphorylation status of Cdc2 at the Tyr-15 residue was determined using an antibody that specifically recognizes the Tyr-15-phosphorylated Cdc2. We found that amifostine treatment resulted in a decrease of Tyr-15-phosphorylated Cdc2 protein through dephosphorylation of Tyr-15 on Cdc2. Olomoucine, a potent Cdc2 inhibitor, effectively prevented amifostineinduced Cdc2 kinase activation and subsequent apoptosis, suggesting that Cdc2 kinase plays an important role in the induction of apoptosis by amifostine. 25 Second, when amifostine was combined with Adp53, we found enhanced sensitivity of cancer cells to cytotoxicity through accumulation of p53 protein. We have illustrated that Adp53 also has an important role in regulating Cdc2 phosphorylation. Treatment of cells with Adp53 resulted in dephosphorylation of Tyr-15 on Cdc2, and olomoucine treatment prevented the dephosphorylation of Tyr-15 on Cdc2 and reduced the amount of subsequent apoptosis. These results suggest that Cdc2 kinase activity is an important determinant of p53-dependent DNA damageinduced apoptosis. 
Cdc2 kinase activation controls the G 2 /M transition by promoting the breakdown of the nuclear membrane, chromatin condensation, and microtubule spindle formation. 26 This kinase is activated by threonine-161 phosphorylation and its association with other proteins, primarily cyclin B1. In several systems, the induction of apoptosis is associated with activation of cyclin B1-Cdc2 kinase activity. [27] [28] [29] [30] [31] [32] The involvement of abnormal activation of Cdc2 kinase in the apoptotic process was first indicated in a hematopoietic cell system. 33, 34 Evidence that Cdc2 kinase activity is required for apoptosis is provided by the observation that overexpression of a dominant-negative Cdc2 kinase mutant blocks Fas/ APO1-induced apoptosis in Jurkat cells. 35 Unscheduled activation of Cdc2 kinase was correlated with the DNA damage-induced apoptosis in promyelocytic leukemia cells, 36 and a persistent elevation of cyclin B1-associated Cdc2 kinase activity was required for activation-induced programmed T-cell death. 37 In addition, activation of cyclin B1-associated Cdc2 kinase has been implicated in apoptotic cancer cell death induced by anticancer agents, such as the microtubule stabilizer paclitaxel, camptothecin, and etoposide. 38 Inhibition of cyclin B1-Cdc2 kinase activity may also represent the mechanism by which some transforming oncogenes protect against apoptosis. 39 In several reports, it has been suggested that Cdc2 kinase activity is a critical modulator of apoptosis triggered by several stimuli. Other reports have indicated that it may not be obligatory for all forms of cell death. Although the increase in Cdc2 kinase activity observed during apoptosis has been reported to be associated with dephosphorylation of Tyr-15-phosphorylated Cdc2, the biological role of Cdc2 kinase activation in the process of apoptosis remains to be investigated. It has been proposed that this kinase could be involved in some of the mechanistic (morphological) changes of apoptosis.
We believe that amifostine, because of its unique dual roles as a cytoprotectant for normal cells and an antitumor agent against malignant cells is of particular interest for further preclinical and clinical development as a therapeutic agent for lung cancer. 
